The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I NRG-GY017
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
NRG Oncology
Mayadev, Jyoti S.
(858) 822-7499
Phase I PBTC-049
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors
Pediatric Brain Tumor Consortium
Salloum, Ralph
(513) 636-1281
Phase II 10191
A Phase 2 Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Dana-Farber – Harvard Cancer Center LAO
Choudhury, Atish Dipankar
(617) 632-6328
Phase II 10193
Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
Mayo Clinic Cancer Center LAO
Bennani, Nabila Nora
(507) 284-2511
Phase II ACNS1721
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations
Children’s Oncology Group
Karajannis, Matthias A.
(212) 639-3171
Phase III A221702
ARM: Axillary Reverse Mapping – A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and without Axillary Reverse Mapping
Alliance for Clinical Trials in Oncology
Klimberg, V. Suzanne
(501) 680-0779
Phase III EA6174
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
ECOG-ACRIN Cancer Research Group
Gastman, Brian R.
(216)-444-6901
Phase III S1714
A Prospective Observational Cohort Study to develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
SWOG
Trivedi, Meghna S.
(212) 305-1945
Phase Other ARST18B3-Q
Development of Circulating Tumor DNA Assays for Embryonal Rhabdomyosarcoma
Children’s Oncology Group
Crompton, Brian
(617) 632-4468
Phase Other WF-1803CD
Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices
Wake Forest NCORP Research Base
Nightingale, Chandylen
(336) 713-1432
